Navigation Links
Lexicon Announces Proposed $95 Million Common Stock Offering
Date:3/8/2010

THE WOODLANDS, Texas, March 8 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.  Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.  All of the shares in the offering are to be sold by Lexicon.  Morgan Stanley & Co. Incorporated and J.P. Morgan Securities Inc. will be acting as joint book-runners for the offering, with Cowen and Company, LLC and Thomas Weisel Partners LLC acting as co-managers.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.  The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus, copies of which may be obtained from Morgan Stanley & Co. Incorporated, Attn:  Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone:  (866) 718-1649, or by emailing prospectus@morganstanley.com, or from J.P. Morgan Securities Inc., Attention: Broadridge Financial Solutions at 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204.

The issuer has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement and related prospectus supplements and other documents that the issuer has filed or will file with the SEC for more complete information about the issuer and this offering.  You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.  Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team.  

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the proposed public offering. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Words such as "will," "intends" and similar expressions are intended to identify these forward-looking statements.  There are a number of important factors that could cause Lexicon's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed public offering.  There can be no assurance that Lexicon will be able to complete the proposed public offering on the anticipated terms, or at all.  Additional risks and uncertainties relating to the proposed public offering, Lexicon and its business can be found under the headings "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission, and under the heading "Risk Factors" in the preliminary prospectus supplement related to the proposed public offering to be filed with the Securities and Exchange Commission on March 8, 2010. Unless required by applicable law, Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.lexpharma.com

'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
2. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
3. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
4. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
5. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
6. Lexicon Announces Completion of Public Offering of Common Stock
7. Lexicon Announces Pricing of Common Stock in Public Offering
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... pharmacies, will be represented at the 2016 Asembia Specialty Pharmacy Summit held May ... is the largest U.S. health care conference for the specialty pharmacy industry, with ...
(Date:5/3/2016)... ... 2016 , ... University of the People, the world’s first ... Associates and Bachelor's degrees in Health Studies. Leading figures are heading the program’s ... Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, Stanley M. Bergman; ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... that it is launching a new client service center in La Vergne, Tennessee, ... and will provide the full range of Empyrean client services. , “Our Nashville-area ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nationally recognized personal injury law firm Monge & ... giving free roses to anyone who wants one for their Mother or any other mother ... important valuable contributions of Mothers.” Monge goes on to say, “we are choosing to ...
(Date:5/3/2016)... ... 2016 , ... Park Cities Pet Sitter has openings for both full-time and ... 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These ... Preston Hollow and Park Cities areas of the Metroplex. Candidates must love animals, ...
Breaking Medicine News(10 mins):